XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Guntimadugu M, Muram Reddy V L, Kharidehal D, Byna S R, Nandam M R, Gelli V S L et al . Expression of Her2/neu in Urothelial Neoplasms and its Association with Histopathological Prognostic Parameters. Journal of Research in Applied and Basic Medical Sciences 2023; 9 (1) :11-23
URL: http://ijrabms.umsu.ac.ir/article-1-215-en.html
Associate Professor, Department of Pathology, Narayana medical college and Hospital, Nellore. Andhra Pradesh, India , vishmireddy@gmail.com
Abstract:   (752 Views)
Background & Aims: Bladder carcinoma is the second common malignancy of the urogenital system. Bladder malignancy encompasses 5.2% of all forms of cancer. According to study, Her2/neu expression can be considered as a prognostic clinical biomarker for bladder cancer. Target therapy using novel and recombinant chemodrugs such as transtuzumab can be applied in Her2/neu positive cases. Current study aimed to evaluate urothelial neoplasms incidence, to assess Her2/neu expression, and to compare its expression with prognostic factors.
Materials & Methods: The present study is a prospective study conducted in the Department of Pathology, Narayana Medical College and General Hospital, Nellore, India, for a period of 2 years from June 2019 to June 2021. All the urothelial neoplasm cases reported during the study period were included, and Her2/neu immunohistochemistry has been assessed for the cases.
Results: Among 71 bladder specimens, 48 had urothelial carcinomas (54% of high grade and 46% of low grade), and 20 had benign neoplasms. Among high-grade carcinomas, 91% were muscle invasive and among low grade, 55% were non-muscle invasive. Lateral wall is the common site of urothelial carcinoma. The mean age for high-grade carcinomas was 61-70 years, and it was associated with higher grades and stages of the tumor. In high grade and low-grade carcinomas, males outnumbered females. A significant correlation observed between tumor grade and stage. A significant association was found between Her2/neu overexpression with the grade and size of the tumor. No association was found between Her2/neu expression and age, gender, stage, and invasion.
Conclusion: It is concluded that identifying the expression of Her2/neu in urothelial carcinoma can help identify eligible candidates for targeted therapy.
Full-Text [PDF 719 kb]   (497 Downloads)    
Type of Study: orginal article | Subject: General

References
1. Nedjadi T, Al-Maghrabi J, Assidi M, Dallol A, Al-Kattabi H, Chaudhary A, et al. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer 2016;16:653. [DOI:10.1002/ijc.31937] [PMID]
2. Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011;59(4):584-94. [DOI:10.1016/j.eururo.2010.12.042] [PMID]
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54(2):303-14. [DOI:10.1016/j.eururo.2008.04.051] [PMID]
4. National Cancer Registry Program. Consolidated Report of Population Based Cancer Registries 2001-2004. [URL]
5. Kumar V, Abbas AK, Fausto N. The lower urinary tract and male genital system. Robbins and Cotran. Pathol Basis Dis 2005:124.
6. Naik DS, Sharma S, Ray A, Hedau S. Epidermal growth factor receptor expression in urinary bladder cancer. Indian Journal of Urology: Indian J Urol 2011;27(2):208. [DOI:10.4103/0970-1591.82839] [PMID] [PMCID]
7. Yuvaraja TB, Waigankar S, Bakshi G, Prakash G. Genitourinary cancers: Summary of Indian data. South Asian J Cancer 2016;5(3):122-4. [DOI:10.4103/2278-330X.187577] [PMID] [PMCID]
8. Van Der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol 2000;164(5):1533-7. https://doi.org/10.1016/S0022-5347(05)67022-X [DOI:10.1097/00005392-200011000-00017] [PMID]
9. BOL MG, BAAK JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, JANSSEN EA, Mestad O, ØGreid PE. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003;169(4):1291-4. [DOI:10.1097/01.ju.0000055471.78783.ae] [PMID]
10. Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA, Bartlett JM. Her2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 2003;89(7):1305-9. [DOI:10.1038/sj.bjc.6601245] [PMID] [PMCID]
11. Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R, Lopez-Beltran A. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59(1):83-8. [DOI:10.1136/jcp.2004.022939] [PMID] [PMCID]
12. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230(4730):1132-9. [DOI:10.1126/science.2999974] [PMID]
13. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989;4(3):362-6. [DOI:10.1016/0888-7543(89)90343-1] [PMID]
14. King C. R., Kraus M. H., Aaronson S. A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229(4717):974-6. [DOI:10.1126/science.2992089] [PMID]
15. Borg A., Tandon A. K., Sigurdsson H., Clark G. M., Ferno M., Fuqua S. A., Killander D., McGuire W. L. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50(14):4332-7 [Google Scholar]
16. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992;10(7):1044-8. [DOI:10.1200/JCO.1992.10.7.1044] [PMID]
17. Stein JP, Lieskovsky G, Cote R. Radical cystectomy in the treatment of bladder cancer: Long term results in 1045 patients. J Clin Oncol 2001;19:666-75. [DOI:10.1200/JCO.2001.19.3.666] [PMID]
18. Lonn U, Lonn S, Friberg S, Nilsson B, Silfverswärd C, Stenkvist B. Prognostin value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995;1:1189-94. [Google Scholar]
19. Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun Y, Xu C. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol 2015;47(1):87-94. [DOI:10.1007/s11255-014-0866-z] [PMID]
20. Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol 2008;130(2):274-81. [DOI:10.1309/41VLTFX3YPP1HF6F] [PMID]
21. Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN, Kumar R. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2008 Jun;40(2):321-7. [DOI:10.1007/s11255-007-9283-x] [PMID]
22. Kurkure AP. Cancer incidence and patterns in urban Maharashtra. Consolidated report of the population based cancer registries. 2001.
23. Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A. Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol 2009;25:207-10. [DOI:10.4103/0970-1591.52916] [PMID] [PMCID]
24. Mungan NA, Aben KK, Schoenberg MP, Visser O, Coebergh JW, Witjies JA, Kiemeney LA. Gender differences in stage adjusted bladder cancer survival. Urology 2000; 55(6):876-80. [DOI:10.1016/S0090-4295(00)00523-9] [PMID]
25. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130:1083-1086. [DOI:10.1016/S0022-5347(17)51695-X] [PMID]
26. Bostwick DG. Natural history of early bladder cancer. J Cell Biochem Suppl 1992;50(16I):31-8. [DOI:10.1002/jcb.240501307] [PMID]
27. Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M. HER2 as a target in invasive urothelial carcinoma. Cancer Med 2015;4(6):844-52. [DOI:10.1002/cam4.432] [PMID] [PMCID]
28. Ismail NEH, El-Nagar SI, Khodeir MM, Ahmed MM. Immunohistochemical study of HER-2/neu expression in urothelial bladder carcinoma. Acad Int J Cancer Res 2015;8(3):35-9
29. Charfi S, khabir A, Mnif H, Ellouze S, Mhiri MN, Boudawara-Sellami T. Immunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation with p53 and p63 expression. J Microsc Ultrastruct 2013;1(1):17-21. [DOI:10.1016/j.jmau.2013.06.001]
30. Nedjadi T, Al-Maghrabi J, Assidi M, Dallol A, Al-Kattabi H, Chaudhary A, et al. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer 2016;16:653. [DOI:10.1186/s12885-016-2703-5] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Research in Applied and Basic Medical Sciences

Designed & Developed by : Yektaweb